Generation II DNA Sequencing Technologies. Spring 09 By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold greater than Gene... Read more...

Of Mice and Men. Winter 08 By Dr Catherine A. Brady The effort to develop drugs that interact with the human immune system (whether by accident or design) has been dogged by a mismatch between the data derived from animal models (mice in p... Read more...

qPCR Assays; end user practices and latest vendor offerings. Winter 2008 By Dr John Comley This review provides an insight into real-time quantitative PCR (qPCR) assays today. Read more...

Emerging Real-time PCR applications. Summer 2008 Dr Mikael Kubista Since its introduction on the commercial market little more than 10 years ago, real-time PCR has become the main technical platform for nucleic acid detection in research and developme... Read more...

Trends in the microRNA Marketplace. Spring 08 By Kathy Gray and Dr Enal Razvi In this article, a recent market analysis is discussed aimed at understanding the market landscape, trends and opportunity in the rapidly-expanding microRNA marketplace. These market anal... Read more...

Monochromator vs Filter-based Plate Readers; horses for courses, or a winning combination?. Fall 2007 By Dr John Comley This article is based around feedback obtained in HTStec’s recent Multi-Mode Microplate Reader Trends 2007 Report. Read more...

21st century Vaccines; a Development Renaissance. Fall 2007 By Dr Jeff Stoddard, Charles Drucker and Dr Nigel Brown Human beings have benefited from vaccines for more than two centuries. From eradicating some of the deadliest diseases to nearly eliminating a host of others, including polio, measles, mu... Read more...

Next Generation DNA Sequencing Technologies. Winter 2007 By Dr Bruce E. Taillon and Brendon Hill Human genetics is the foundation of disease as well as the response to pharmaceutical agents. Today, promising drugs are abandoned due to the lack of significant efficacy in broad patient... Read more...